Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to afamitresgene autoleucel for certain adults with unresectable or ...

A PDUFA target date of August 4, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for ...

Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors Adoptive immunotherapy using tumor-infiltrating lymphocytes ...

Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional ...

Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review. The Food and Drug Administration (FDA) has ...

Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found. The group irradiated ...

In the sport of sumo, a bout most commonly ends when one competitor is pushed or thrown outside of a ring of straw bales partially buried in clay. New research shows that using a drug as a blocker to ...

Researchers have developed a way to attack synovial sarcoma -- a rare tumor of soft tissues, such as ligaments and muscles -- using an investigational drug that triggers cell death. Researchers at ...

A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and ...

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma - a rare tumor of soft tissues, such as ligaments and muscles - using an ...